Objective Some private health screening companies in the UK provide 'health check-ups' using whole-body magnetic resonance imaging (MRI), in spite of the lack of evidence demonstrating that such screening is worthwhile. We discuss the issues surrounding the use of an MRI scan as a screening test in 'health check-ups' and set out our concerns. Conclusion Because of the five balance between the potential perils and benefits of the unselective use of brain MRI for 'health check-ups', its use should be restricted to a research setting.
Objective Some private health screening companies in the UK provide 'health check-ups' using whole-body magnetic resonance imaging (MRI), in spite of the lack of evidence demonstrating that such screening is worthwhile. We discuss the issues surrounding the use of an MRI scan as a screening test in 'health check-ups' and set out our concerns. Conclusion Because of the five balance between the potential perils and benefits of the unselective use of brain MRI for 'health check-ups', its use should be restricted to a research setting. S everal companies in the UK now offer 'health MOTs' at a cost of between a few hundred and several thousand pounds. A Consumer's Association Report on health screening services, published in 2004, estimated that Britain spends £65 million each year on private health screening, but warned that, 'while private clinics would have you believe that paying for a barrage of health checks is the key to your future health, there's little evidence to back this up'.
Most 'health MOTs' begin with a lifestyle review. Although a search of the Cochrane Library reveals that only a few lifestyle interventions are supported by good evidence from randomized trials, 1 it is difficult to dispute the promotion of a healthy lifestyle. However, much more than a lifestyle review is usually included in the 'health assessments ' and 'check-ups' The variety of tests on offer in a health MOT is designed to detect undiagnosed problems and minimize their consequences through treatment or prevention. In other words, these health MOTs, check-ups, and assessments are screening by another name. The requirements of a screening test do not need reiteration in this Journal, but fundamentally they should rely on the discovery of any abnormality whose management results in an increase in the number of quality-adjusted life years for the individual concerned. Unfortunately, many of the tests provided by health screening companies are expensive or lack evidence that beneficial effects, such as improving disease-free survival, outweigh harmful effects, such as the hazards associated with the treatment of asymptomatic abnormalities detected as a result of the screening test ('incidentalomas'). [2] [3] [4] [5] 
WHOLE-BODY MAGNETIC RESONANCE IMAGING: THE CASE OF PREVENTICUM
In spite of the paucity of evidence showing benefits, some companies in the UK go further and offer whole-body CT or MRI. These investigations are available with 'no questions asked' elsewhere in the world (USA and Japan, for example), but one hopes that the personalized consultation with a doctor offered by these UK companies will result in only an appropriate, evidence-based purchase of these investigations by the consumer. To check whether this is the case, we can only rely on the World Wide Web and newspapers to find evidence of selective use of these investigations; for example, The Diagnostic Clinic states that MRI is not part of standard screening because ' [it] should only be performed when absolutely necessary'.
Preventicum, however, offers as part of its £2,750 '6-star service' 'Ultimate Check-Up', whole-body MRI screening. To quote from www.preventicum.co.uk, 'The centre-piece of the check-up is a unique, radiation-free Magnetic Resonance Imaging scan, which takes hundreds of images of the body without any known side-effects. This highly innovative technology provides detailed images of the heart, blood vessels, brain, abdomen and colon.' The potential perils of indiscriminate MRI screening are illustrated by the following case study, which was reported in the national press and is the substance of the first 'testimonial' on Preventicum's website.
A CASE REPORT FROM PREVENTICUM
On Thursday 20 April 2006, in an article entitled 'I was terrified that I would die any minute', The Guardian told the story of a celebrity professional in her mid-thirties who thought she, 'had an allergic reaction, probably to nuts, and wanted to get to the bottom of it so [she] went to a company called Preventicum that offers state-of-the-art screening, including a full-body MRI scan'. The MRI of her brain revealed an asymptomatic incidentaloma, unrelated to her presenting complaint: an unruptured intracranial aneurysm. Her story, as told by The Guardian, illustrates some of the detrimental effects of detecting an incidentaloma by inappropriate screening: she reads horror stories about other patients with aneurysms on the World Wide Web, she finds discussing further management with medical staff to be difficult, as a celebrity with a medical condition she is put in the media spotlight, and she is afraid of immediate death or stroke both before treatment and even several months afterwards. Happily, her aneurysm was treated successfully by endovascular coiling (at least at her initial angiographic follow-up), but she is now left with a lifetime of follow-up angiography ahead of her, to check that the aneurysm remains occluded and that no new aneurysms appear. Although portrayed as a life-saving success story, it is impossible to say whether her aneurysm would have ever bled, and the case report clearly illustrates not only the potential adverse consequences of indiscriminate screening in general but also the specific dangers of inappropriate brain MRI.
THE FREQUENCY OF INCIDENTALOMAS ON BRAIN MRI
Any doctor working for a screening company who requests brain MRI no doubt considers its necessity as well as the risk of identifying an incidentaloma. Data on the prevalence of incidentalomas come from studies of a total of 7359 adults, using axial brain MRI without angiographic sequences (Table 1 ). [6] [7] [8] [9] The individuals in these studies were: healthy men aged 17-35 years applying for military flying duties in the German Air Force 6 (an updated account of previous reports 10, 11 ), healthy asymptomatic volunteers aged 3-83 years 7 and 18-90 years, 9 and the Cardiovascular Health Study of consenting community residents aged >65 years who were able to walk and communicate but were not terminally ill. 8 Compared to the Cardiovascular Health Study, 8 the studies of healthy individuals accounted for all of the brain arteriovenous malformations identified 6, 9 and more than half of the cavernous malformations, 6,7,9 but only one-fifth of the aneurysms 7 and one-third of the lowgrade tumours. 6, 7 The chance of finding an incidentaloma is clearly age-related. Furthermore, the chance of detecting an unruptured intracranial aneurysm depends on the type of imaging; with angiographic MRI sequences, the prevalence of intracranial aneurysms in people without a family history of aneurysms or an associated genetic condition is approximately 2%, 12 much higher than the proportion in studies using axial brain MRI alone (Table 1) .
SCREENING FOR UNRUPTURED INTRACRANIAL ANEURYSMS
Returning to the Preventicum case, we cannot think of a clinical reason for performing a whole-body MRI scan for a young woman who presented with a probable nut allergy: the potential reassurance gained from a normal scan is likely to be outweighed by both the financial cost as well as the risks of discovering one or more incidentalomas.
When screening for intracranial aneurysms, the lifetime risk of subarachnoid haemorrhage in the screened group must be borne in mind. For someone like the woman in the case report, without any affected first-degree relatives, her lifetime risk of subarachnoid haemorrhage is 0.6% (95% confidence interval [CI] 0.6-0.7). 12 Because the overall prevalence of unruptured aneurysms is approximately 2%, this implies that most intracranial aneurysms never bleed. In a sense, for every person that screening finds to have an unruptured aneurysm that would have bled at some time in the future (a 'true positive'), there would be at least two people that screening finds to have an unruptured aneurysm that would never bleed ('false positives'). Once identified by screening, it is very hard to tell whether an unruptured intracranial aneurysm is a true or false positive.
The risks of treating unruptured intracranial aneurysms are not trivial. By way of a simplified example based on the figures above, if 1000 adults in their fifties -without a prior history of subarachnoid haemorrhage -were screened with angiography, then approximately 20 intracranial aneurysms would be discovered (six of which would have bled in the future, and 14 would not). If all 20 of these adults had their aneurysm treated by endovascular coiling, then two of them would be dead, disabled, or cognitively impaired by one year after the procedure. 13 Furthermore, eight of these aneurysms would not even have been completely occluded by endovascular coiling, still leaving a patient at risk of a future subarachnoid haemorrhage. If these potential adverse outcomes do not seem unattractive enough, bear in mind that the risk of a poor outcome from treatment increases further if the patient is older as well as if the aneurysm is large, and/ or located on the posterior circulation, and/or treated surgically rather than endovascularly. 13 The balance between the risks and the benefit of screening for and then treating unruptured intracranial aneurysms in the general population means that it cannot be recommended outside the context of a research study.
The only plausible indication for the woman in the case report having a brain MRI might have been that she was at Table1 Incidental findings on brain magnetic resonance imaging scans of 7359 healthy volunteers (imaging sequences did not include magnetic resonance angiography) [6] [7] [8] [9] Abnormality n % 95% CI 1 in y higher risk of harbouring an intracranial aneurysm than the general population. The newspaper article mentioned that she had a family history of a ruptured intracranial aneurysm affecting one second-degree relative (her uncle, in his early 40s). Even then, the rise in lifetime risk of aneurysmal subarachnoid haemorrhage for someone who has one affected second-degree relative is negligible. However, the risk does rise from 0.6% to 3.3% (95% CI 1.0-11.0) for someone with one affected first-degree relative. 12 The lifetime risk of aneurysmal subarachnoid haemorrhage is higher still for people with autosomal dominant polycystic kidney disease or adults with two or more first-degree relatives with aneurysmal subarachnoid haemorrhage (the risk is highest when the affected relatives are siblings), so these are the usual target groups for screening. 12 The choice of these target groups for screening is based on case-control studies of the relative risk of these particular patient groups harbouring an aneurysm, rather than randomized trials. The consequences of screening for intracranial aneurysms are still potentially detrimental, even in young, fit people with an appropriate family history and/or autosomal dominant polycystic kidney disease.
Complete reassurance for the woman in the case report is not even possible after treatment of her aneurysm, because further aneurysms may yet develop: patients are thereby exposed to the stresses of repeated screening (whose optimum interval and duration remain unknown), prior to which an aneurysmal subarachnoid haemorrhage might still occur. Even if a further aneurysm is identified by follow-up angiography, it might be too small to be treatable, and this knowledge is likely to impair quality of life. 14 
WHAT IS THE FUTURE FOR WHOLE-BODY MAGNETIC RESONANCE IMAGING SCREENING, AND INCIDENTALOMAS?
As the availability, uptake, and resolution of imaging increases, incidentalomas (or incidental 'Oh My!'s 15 ) will become an even more frequent problem. Mindful of our reservations about whole-body MRI and Preventicum's salutary case report, what should be done? Any doctor currently requesting whole-body screening for an otherwise healthy patient would be wise to check that their indemnity provider will cover such requests. 16 Undoubtedly, further research is needed to establish whether whole-body screening is effective, although it would require a very large Because of their commercial imperative, health 'check up' companies have a competing interest when trying to provide impartial, evidence-based advice about screening. The London Preventicum clinic is a satellite of the German clinic based in the University Hospital Essen. Interestingly, the Department of Diagnostic and Interventional Radiology at the University Hospital Essen published a paper on their whole-body MRI screening technique and concluded that, 'screening MRI should not be performed outside a research setting because the cost-benefit relation is unclear'. 17 As there are no robust data to support the use of brain or whole-body scanning as a screening tool, companies' clients should be informed, if they are not already, of the lack of evidence and potential for harm by unwarranted imaging.
